^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TT-816

    i
    Other names: TT-816
    Associations

    News

    Trials
    Company:
    Teon Therap
    Drug class:
    Cannabinoid receptor 2 antagonist
    Associations

    News

    Trials
    over2years
    TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88) (clinicaltrials.gov)
    P1/2, N=9, Terminated, Teon Therapeutics, Inc. | N=200 --> 9 | Trial completion date: Aug 2027 --> Sep 2023 | Active, not recruiting --> Terminated; Company operational decision. Decision to stop study is not due to safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination • Combination therapy • Metastases
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • TT-816
    over2years
    TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88) (clinicaltrials.gov)
    P1/2, N=200, Active, not recruiting, Teon Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • TT-816